The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study
- PMID: 33594986
- DOI: 10.1016/j.numecd.2020.09.014
The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study
Abstract
Background and aim: Vascular calcification is an independent risk factor for cardiovascular diseases and all-cause mortality in end stage renal disease, and particularly in hemodialysis patients. Vitamin D deficiency has been shown to be associated with vascular calcification among this category of patients. Cholecalciferol or vitamin D3; the native inactivated 25-hydroxy vitamin D [25(OH)D], has been proposed to have a good impact on vascular calcification and vitamin D deficiency. However, clinical data is still limited.
Methods and results: A prospective, randomized, placebo-controlled study was carried out to evaluate the effect of oral cholecalciferol on vascular calcification and 25(OH)D levels in hemodialysis patients. A total of sixty eligible hemodialysis patients were randomly assigned to either a treatment group (Oral 200.000IU Cholecalciferol per month) or a placebo group, for 3 months. Serum 25-hydroxy vitamin D (25(OH)D), fetuin-A, fibroblast growth factor (FGF-23), osteoprotegerin (OPG), calcium, phosphorus, their product (CaXP) and intact parathyroid hormone (iPTH) levels, were all assessed at baseline and at the end of the study. ClinicalTrials.gov registration number: NCT03602430. Cholecalciferol significantly increased serum levels of 25(OH)D and fetuin-A in the treatment group (p-value < 0.001), while no significant difference was observed in the placebo group. Cholecalciferol administration showed no effect on either FGF-23 or OPG. None of the treatment group patients experienced any adverse effects.
Conclusion: Cholecalciferol was shown to be an effective, tolerable, inexpensive pharmacotherapeutic option to overcome vitamin D deficiency, with a possible modulating effect on fetuin-A, among hemodialysis patients. CLINICALTRIALS.
Gov registration number: NCT03602430.
Keywords: 25(OH)D; Cholecalciferol; FGF-23; Fetuin-A; Hemodialysis; OPG; Vascular calcification.
Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None declared.
Similar articles
-
Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.Clin J Am Soc Nephrol. 2013 Jul;8(7):1143-9. doi: 10.2215/CJN.02840312. Epub 2013 Mar 14. Clin J Am Soc Nephrol. 2013. PMID: 23493381 Free PMC article. Clinical Trial.
-
Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.Am J Kidney Dis. 2014 Nov;64(5):696-705. doi: 10.1053/j.ajkd.2014.04.020. Epub 2014 May 22. Am J Kidney Dis. 2014. PMID: 24856872 Clinical Trial.
-
The Effect of Long-Term Cholecalciferol Supplementation on Vascular Calcification in Chronic Kidney Disease Patients With Hypovitaminosis D.J Ren Nutr. 2019 Sep;29(5):407-415. doi: 10.1053/j.jrn.2018.12.002. Epub 2019 Jan 25. J Ren Nutr. 2019. PMID: 30686750 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Screening for Vitamin D Deficiency in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2021 Apr 13;325(14):1443-1463. doi: 10.1001/jama.2020.26498. JAMA. 2021. PMID: 33847712
Cited by
-
A genetic insight into vitamin D binding protein and COVID-19.Med Hypotheses. 2021 Apr;149:110531. doi: 10.1016/j.mehy.2021.110531. Epub 2021 Feb 9. Med Hypotheses. 2021. PMID: 33607405 Free PMC article.
-
Causal association pathways between fetuin-A and kidney function: a mediation analysis.J Int Med Res. 2022 Apr;50(4):3000605221082874. doi: 10.1177/03000605221082874. J Int Med Res. 2022. PMID: 35435033 Free PMC article.
-
Clinical significance of serum CDC42 in the prediction of uremic vascular calcification incidence and progression.Libyan J Med. 2023 Dec;18(1):2194100. doi: 10.1080/19932820.2023.2194100. Libyan J Med. 2023. PMID: 36987774 Free PMC article.
-
The Role of Daily Dialysate Calcium Exposure in Phosphaturic Hormones in Dialysis Patients.Life (Basel). 2024 Jul 31;14(8):964. doi: 10.3390/life14080964. Life (Basel). 2024. PMID: 39202706 Free PMC article.
-
Association between 25 hydroxyvitamin D and serum uric acid level in the Chinese general population: a cross-sectional study.BMC Endocr Disord. 2024 Sep 12;24(1):187. doi: 10.1186/s12902-024-01723-0. BMC Endocr Disord. 2024. PMID: 39261907 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous